{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:14:39Z","timestamp":1787764479383,"version":"build-2784847793"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Beh\u00e7et\u2019s disease (BD) is a chronic, relapsing, multisystem inflammatory disorder, with ocular involvement being a major cause of irreversible visual impairment. Beh\u00e7et\u2019s uveitis (BU) often presents as bilateral, recurrent, non-granulomatous panuveitis with occlusive retinal vasculitis. Despite advances in immunosuppressive and biologic therapies, long-term visual outcomes remain variable, and factors associated with poor prognosis, particularly in Chinese populations, are not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 153 Chinese patients (268 eyes) with BU at Peking Union Medical College Hospital from February 2003 to February 2023. Clinical records, ocular examinations, and systemic manifestations were reviewed. The primary endpoint was severe visual impairment (best-corrected visual acuity [BCVA] &amp;lt;20\/200) at the final follow-up. Secondary endpoints included ocular complications and their impact on visual outcomes. Kaplan\u2013Meier survival analysis and mixed-effects logistic regression (accounting for inter-eye correlation) were used to evaluate risk factors for poor visual prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the cohort, 77.8% were male, and bilateral involvement occurred in 84.3%. Median follow-up was 30 months. Panuveitis was the predominant form (90.3%), and cataract (64.9%) and macular edema (63.1%) were the most common complications. At final follow-up, 25.4% of eyes had BCVA &amp;lt;20\/200. Kaplan\u2013Meier analysis showed cumulative risk of severe visual loss of 3.5% at 1 year, 11.0% at 2 years, 19.2% at 5 years, and 41.4% at 10 years. Male patients experienced visual impairment earlier than females. Mixed-effects logistic regression identified macular damage (p=0.027, OR = 3.70) and optic nerve atrophy (p&amp;lt;0.001, OR = 6.47) as significant predictors of poor visual outcomes, while complete-type BD showed a trend toward association (p=0.072, OR = 2.00). Systemic disease severity was not significantly associated with visual prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this Chinese cohort with BU, irreversible ocular structural damage, particularly macular damage and optic nerve atrophy, was the primary determinant of long-term visual outcomes. Systemic disease severity had limited predictive value. Despite improvements compared with historical data, these findings highlight the critical importance of early recognition and effective management of posterior segment inflammation to prevent permanent visual impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1617653","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:36:20Z","timestamp":1773758180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Visual prognosis of Beh\u00e7et\u2019s uveitis patients in China and its associated factors"],"prefix":"10.3389","volume":"17","author":[{"given":"Minghang","family":"Pei","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Fourth People\u2019s Hospital of Shenyang","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00535-024-02191-y","article-title":"Beh\u00e7et\u2019s disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan","volume":"60","author":"Hisamatsu","year":"2025","journal-title":"J Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/BOR.0000000000000911","article-title":"Uveitis in Beh\u00e7et disease - an update","volume":"35","author":"Tugal-Tutkun","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14075","article-title":"Comparison of relapse rates in Beh\u00e7et\u2019s disease with venous involvement on different doses of azathioprine therapy, a retrospective observational study","volume":"24","author":"Girgin","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107812","article-title":"Specific sweat metabolite profile in ocular Behcet\u2019s disease","volume":"97","author":"Cui","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma2021137051130","article-title":"Beh\u00e7et\u2019s disease and uveitis","volume":"137","author":"Razumova","year":"2021","journal-title":"Vestnik Oftalmologii"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.968345","article-title":"Beh\u00e7et uveitis: Current practice and future perspectives","volume":"9","author":"Aboul Naga","year":"2022","journal-title":"Front Med (Laus)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1206959","article-title":"Advances in pathogenesis and treatment of ocular involvement in Behcet\u2019s disease","volume":"14","author":"Lin","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13075-022-02782-1","article-title":"Clinical heterogeneity of ocular Beh\u00e7et\u2019s syndrome versus intestinal Beh\u00e7et\u2019s syndrome: a cross-sectional study from Shanghai Beh\u00e7et\u2019s syndrome database","volume":"24","author":"Hou","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-017-1691-z","article-title":"Quality of life impairment in Beh\u00e7et\u2019s disease and relationship with disease activity: a prospective study","volume":"12","author":"Fabiani","year":"2017","journal-title":"Intern Emerg Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105819","article-title":"Influence of gender on Beh\u00e7et\u2019s disease phenotype and irreversible organ damage: Data from the International AIDA Network Beh\u00e7et\u2019s Disease Registry","volume":"92","author":"Sota","year":"2025","journal-title":"Joint Bone Spine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-024-00916-z","article-title":"Ocular manifestations in juvenile beh\u00e7et\u2019s disease: A registry-based analysis from the AIDA network","volume":"13","author":"Gaggiano","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6872402","article-title":"Long-term outcomes of beh\u00e7et\u2019s syndrome-related uveitis: A monocentric italian experience","volume":"2020","author":"Sota","year":"2020","journal-title":"Mediators Inflammation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/09273948.2024.2346815","article-title":"Impact of HLA-B51 on uveitis and retinal vasculitis: data from the AIDA international network registries on ocular inflammatory disorders","volume":"33","author":"Sota","year":"2025","journal-title":"Ocul Immunol Inflammation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08809-2","article-title":"Clinical manifestations and management of pediatric beh\u00e7et\u2019s disease","volume":"61","author":"Hu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-019-02046-y","article-title":"Phenotypes in beh\u00e7et\u2019s syndrome","volume":"14","author":"Seyahi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"B16","article-title":"International study group for Behcet's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1999.tb02023.x","article-title":"Recurrent aphthous stomatitis in Behcet\u2019s disease: clinical features and correlation with systemic disease expression and severity","volume":"28","author":"Krause","year":"1999","journal-title":"J Oral Pathol Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00403-007-0794-1","article-title":"Relationship between periodontal findings and specific polymorphisms of interleukin-1alpha and -1beta in Turkish patients with Behcet\u2019s disease","volume":"300","author":"Akman","year":"2008","journal-title":"Arch Dermatol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-836147","article-title":"Behcet\u2019s disease","volume":"25","author":"Kurokawa","year":"2004","journal-title":"Semin Respir Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.589639","article-title":"Genetic association of interleukin 33\/ST2 polymorphisms with behcet's uveitis","volume":"12","author":"Pei","year":"2021","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.04.056","article-title":"Clinical features of chinese patients with Behcet\u2019s disease","volume":"115","author":"Yang","year":"2008","journal-title":"Ophthalmology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113648","article-title":"Beh\u00e7et\u2019s disease uveitis","volume":"12","author":"Joubert","year":"2023","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.713159","article-title":"Comparison of presenting features and three-year disease course in Turkish patients with Beh\u00e7et uveitis who presented in the early 1990s and the early 2000s","volume":"20","author":"Cingu","year":"2012","journal-title":"Ocul Immunol Inflammation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.031","article-title":"Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"127","author":"Al-Janabi","year":"2020","journal-title":"Ophthalmology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/09273948.2022.2157288","article-title":"Efficacy and safety of adalimumab in patients with beh\u00e7et uveitis: A systematic review and meta-analysis","volume":"32","author":"Sener","year":"2024","journal-title":"Ocul Immunol Inflammation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1095423","article-title":"Ten-year follow-up of infliximab treatment for uveitis in Beh\u00e7et disease patients: A multicenter retrospective study","volume":"10","author":"Takeuchi","year":"2023","journal-title":"Front Med (Laus)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S285400","article-title":"Recent insights into the management of beh\u00e7et syndrome","volume":"14","author":"Ozguler","year":"2021","journal-title":"J Inflammation Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109657","article-title":"Clinical trait-specific genetic analysis in Beh\u00e7et\u2019s disease identifies novel loci associated with ocular and neurological involvement","volume":"253","author":"Casares-Marfil","year":"2023","journal-title":"Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101216","article-title":"Risk factors, clinical features and treatment of Beh\u00e7et\u2019s disease uveitis","volume":"97","author":"Zhong","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-021-01011-z","article-title":"Advances in the treatment of behcet\u2019s disease","volume":"23","author":"Alibaz-Oner","year":"2021","journal-title":"Curr Rheumatol Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1617653\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:36:20Z","timestamp":1773758180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1617653\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1617653"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1617653","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"article-number":"1617653"}}